Why Acadia Pharmaceuticals Stock Is Rocketing Today
Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) rose by as much as 19.2% in premarket trading Tuesday morning. The biotech's stock is taking flight today in response to a positive clinical readout for its experimental Rett syndrome drug known as trofinetide.
Rett syndrome is a rare genetic disorder characterized by the progressive degeneration of motor and speech skills. This inherited disorder affects girls almost exclusively.
Image source: Getty Images.
Source Fool.com
